Document is current
Any future updates will be listed below
-
Authors
Wein, Simon https://orcid.org/0000-0001-9366-2406
Riebel, Marco
Seidel, Philipp
Brunner, Lisa-Marie
Wagner, Viola
Nothdurfter, Caroline
Rupprecht, Rainer
Schwarzbach, Jens V. https://orcid.org/0000-0002-0303-6979
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (422179811, 422179811, 422179811)
- License Information
-
More Information
Article History
Received: 19 September 2023
Revised: 29 April 2024
Accepted: 2 May 2024
First Online: 31 May 2024
Competing interests
: SW, MR, LMB, PS, VW, CN, and JS declare no conflicts of interest. RR has served as a consultant for Biogen and SAGA Therapeutics.
: The study was approved by the local ethics committee (approval number 18-1197-111) and the National Institute for Pharmaceutical Security (BfArM, Eudra-CT-number: 2018-002181-40). All participants gave their written informed consent at the beginning of the experiment.
